Comparison · NCT01703208-7b4bce40
Omarigliptin 25 mg vs Placebo: Number of Participants With an Event of CV-Related Death
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
2 sourcestrial-comparisons-2026-03-23-0.1.0
Cite this record
ConductScience Library. Omarigliptin 25 mg vs Placebo: Number of Participants With an Event of CV-Related Death. Trial comparisons, record NCT01703208-7b4bce40. Release trial-comparisons-2026-03-23-0.1.0, 23 Mar 2026. https://conductscience.org/library/comparisons/NCT01703208-7b4bce40
On this page
Measures6
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
| Measure | Value | 95% interval, lower | 95% interval, upper | Method | Note |
|---|---|---|---|---|---|
| Risk in group 1 | 0.0177 | 0.0129 | 0.0243 | wilson | |
| Risk in group 2 | 0.0167 | 0.012 | 0.0231 | wilson | |
| Risk difference, group 1 minus group 2 | 0.00102 | -0.00702 | 0.00909 | newcombe hybrid score | |
| Risk ratio, group 1 over group 2 | 1.06 | 0.671 | 1.68 | log | |
| Odds ratio, group 1 over group 2 | 1.06 | 0.666 | 1.69 | log | |
| Number needed to treat, for one more participant with the outcome on Omarigliptin 25 mg than on Placebo | 981 | from the risk difference interval | the interval includes no difference |
Source ClinicalTrials.gov
Groups2
Group 2 names the comparator: placebo.
| Group | Title | Description | With the outcome | Analysed | ClinicalTrials.gov code |
|---|---|---|---|---|---|
| Group 1 | Omarigliptin 25 mg | Omarigliptin (MK-3102) 25 mg capsule or tablet administered orally once weekly | 37 | 2,092 | OG000 |
| Group 2 | Placebo | Matching placebo to omarigliptin capsule or tablet administered once weekly. | 35 | 2,100 | OG001 |
Source ClinicalTrials.gov
Outcome
- Type
- SECONDARY
- Title
- Number of Participants With an Event of CV-Related Death
- Description
- Participants with adjudicated and confirmed AEs of cardiovascular-related death.
- Time frame
- Up to 179 weeks
- Population
- The analysis population consisted of all randomized participants who received at least one dose of blinded study medication.
Source ClinicalTrials.gov
Trial
- Title
- A Study to Assess Cardiovascular Outcomes Following Treatment With Omarigliptin (MK-3102) in Participants With Type 2 Diabetes Mellitus (MK-3102-018)
- NCT number
- NCT01703208
- Phases
- PHASE3
- Conditions
- Type 2 Diabetes Mellitus
- Interventions
- Omarigliptin, Placebo
- Lead sponsor
- Merck Sharp & Dohme LLC
- Results first posted
- 2017-12-12
- Results on ClinicalTrials.gov
- https://clinicaltrials.gov/study/NCT01703208?tab=results
Source ClinicalTrials.gov
Source
- Release
- trial-comparisons-2026-03-23-0.1.0
- Release manifest SHA-256
- f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57
- AACT copy
- 2026-03-23
- Tables read
- outcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquet
Source ClinicalTrials.gov
Sources 2
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.
For software
Read this comparison from software.
The record is JSON. No key.
GET https://conductscience.org/api/comparisons/v1/NCT01703208-7b4bce40